BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 11252664)

  • 1. Lithium and synaptic plasticity.
    Salinas PC; Hall AC
    Bipolar Disord; 1999 Dec; 1(2):87-90. PubMed ID: 11252664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valproate regulates GSK-3-mediated axonal remodeling and synapsin I clustering in developing neurons.
    Hall AC; Brennan A; Goold RG; Cleverley K; Lucas FR; Gordon-Weeks PR; Salinas PC
    Mol Cell Neurosci; 2002 Jun; 20(2):257-70. PubMed ID: 12093158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lithium and Therapeutic Targeting of GSK-3.
    Snitow ME; Bhansali RS; Klein PS
    Cells; 2021 Jan; 10(2):. PubMed ID: 33525562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lithium-related genetics of bipolar disorder.
    Detera-Wadleigh SD
    Ann Med; 2001 May; 33(4):272-85. PubMed ID: 11405549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lithium and bipolar mood disorder: the inositol-depletion hypothesis revisited.
    Harwood AJ
    Mol Psychiatry; 2005 Jan; 10(1):117-26. PubMed ID: 15558078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular plasticity cascades: genes-to-behavior pathways in animal models of bipolar disorder.
    Einat H; Manji HK
    Biol Psychiatry; 2006 Jun; 59(12):1160-71. PubMed ID: 16457783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Advances in the Pharmacology and Toxicology of Lithium: A Neurobiologically Oriented Overview.
    Bortolozzi A; Fico G; Berk M; Solmi M; Fornaro M; Quevedo J; Zarate CA; Kessing LV; Vieta E; Carvalho AF
    Pharmacol Rev; 2024 May; 76(3):323-357. PubMed ID: 38697859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphocyte Phospho-Ser-9-GSK-3β/Total GSK-3β Protein Levels Ratio Is Not Affected by Chronic Lithium or Valproate Treatment in Euthymic Patients With Bipolar Disorder.
    Azab AN; Vainer E; Agam G; Bersudsky Y
    J Clin Psychopharmacol; 2017 Apr; 37(2):226-230. PubMed ID: 28106616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycogen synthase kinase-3β activity and cognitive functioning in patients with bipolar I disorder.
    Munkholm K; Miskowiak KW; Jacoby AS; Vinberg M; Leme Talib L; Gattaz WF; Kessing LV
    Eur Neuropsychopharmacol; 2018 Mar; 28(3):361-368. PubMed ID: 29433844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lithium and neuropsychiatric therapeutics: neuroplasticity via glycogen synthase kinase-3beta, beta-catenin, and neurotrophin cascades.
    Wada A
    J Pharmacol Sci; 2009 May; 110(1):14-28. PubMed ID: 19423950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The high affinity inositol transport system--implications for the pathophysiology and treatment of bipolar disorder.
    van Calker D; Belmaker RH
    Bipolar Disord; 2000 Jun; 2(2):102-7. PubMed ID: 11252649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lithium and valproate act on the GSK-3β signaling pathway to reverse manic-like behavior in an animal model of mania induced by ouabain.
    Valvassori SS; Dal-Pont GC; Resende WR; Jornada LK; Peterle BR; Machado AG; Farias HR; de Souza CT; Carvalho AF; Quevedo J
    Neuropharmacology; 2017 May; 117():447-459. PubMed ID: 27789311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycogen synthase kinase-3: a target for novel bipolar disorder treatments.
    Gould TD; Zarate CA; Manji HK
    J Clin Psychiatry; 2004 Jan; 65(1):10-21. PubMed ID: 14744163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abnormalities in protein kinase C signaling and the pathophysiology of bipolar disorder.
    Hahn CG; Friedman E
    Bipolar Disord; 1999 Dec; 1(2):81-6. PubMed ID: 11252663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycogen Synthase Kinase-3β as a Putative Therapeutic Target for Bipolar Disorder.
    Dandekar MP; Valvassori SS; Dal-Pont GC; Quevedo J
    Curr Drug Metab; 2018; 19(8):663-673. PubMed ID: 29283064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lithium regulates glycogen synthase kinase-3beta in human peripheral blood mononuclear cells: implication in the treatment of bipolar disorder.
    Li X; Friedman AB; Zhu W; Wang L; Boswell S; May RS; Davis LL; Jope RS
    Biol Psychiatry; 2007 Jan; 61(2):216-22. PubMed ID: 16806104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3.
    Chen G; Huang LD; Jiang YM; Manji HK
    J Neurochem; 1999 Mar; 72(3):1327-30. PubMed ID: 10037507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lithium Pharmacology and a Potential Role of Lithium on Methamphetamine Abuse and Dependence.
    Kitanaka N; Hall FS; Uhl GR; Kitanaka J
    Curr Drug Res Rev; 2019; 11(2):85-91. PubMed ID: 31875781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview of the mechanism of action of lithium in the brain: fifty-year update.
    Lenox RH; Hahn CG
    J Clin Psychiatry; 2000; 61 Suppl 9():5-15. PubMed ID: 10826655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ziskind-Somerfeld Research Award. Protein kinase C signaling in the brain: molecular transduction of mood stabilization in the treatment of manic-depressive illness.
    Manji HK; Lenox RH
    Biol Psychiatry; 1999 Nov; 46(10):1328-51. PubMed ID: 10578449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.